Biocompatibility Testing of Medical Self-Adhesive Labels: Standards, Test Items, and Methods

Biocompatibility testing of medical self-adhesive labels evaluates the biological safety of label materials—including facestock, pressure-sensitive adhesives, inks, and coatings—that may contact human skin or tissue during clinical use. Performed in accordance with the ISO 10993 and GB/T 16886 series of standards, this testing verifies that labels used on medical devices, patient identification wristbands, wound dressings, and transdermal systems are free from cytotoxic, sensitizing, and irritant hazards. This article outlines the technical framework, sample requirements, test items, evaluation methods, and typical applications involved in the biological safety assessment of medical adhesive labels.

Technical Overview

Medical self-adhesive labels are composite pressure-sensitive products consisting of a facestock material (paper or plastic film), an adhesive layer, a release liner, and, in many cases, printed inks, varnishes, or overlaminates. When these labels are applied to skin-contacting medical products, or when they form part of a device that touches the patient, their biological safety must be demonstrated before market release.

The evaluation follows a risk-based approach established in ISO 10993-1 (biological evaluation of medical devices within a risk management process, aligned with ISO 14971). Because adhesive labels are typically classified as surface-contacting devices with skin contact, the contact duration determines the required endpoints: limited contact (less than 24 hours), prolonged contact (24 hours to 30 days), or long-term contact (more than 30 days). For skin-contacting surface devices, the baseline biological endpoints are cytotoxicity, sensitization, and irritation or intracutaneous reactivity.

Adhesive materials warrant particular attention because pressure-sensitive formulations may contain residual monomers, tackifying resins, plasticizers, antioxidants, and rubber accelerators—several of which are well-documented contact allergens. Occlusion, perspiration, skin temperature, and wear duration can all increase the migration of these substances from the label into the skin, which is why biological testing and chemical characterization are central to the safety assessment.

• ISO 10993-1: Evaluation and testing within a risk management process
• ISO 10993-2: Animal welfare requirements
• ISO 10993-5: Tests for in vitro cytotoxicity
• ISO 10993-10: Tests for skin sensitization
• ISO 10993-23: Tests for irritation
• ISO 10993-11: Tests for systemic toxicity
• ISO 10993-12: Sample preparation and reference materials
• ISO 10993-17: Toxicological risk assessment and allowable limits
• ISO 10993-18: Chemical characterization of medical device materials
• GB/T 16886 series: Chinese national adoption of ISO 10993, applicable for domestic regulatory submissions

Testing Samples

Facestock Materials

Facestock substrates submitted for testing include coated papers, thermal papers, synthetic papers, and plastic films such as PET, PE, PP, and flexible PVC. Test specimens are cut to defined surface areas so that extraction ratios can be calculated reproducibly, and both printed and unprinted areas are evaluated when relevant to the final product configuration.

Pressure-Sensitive Adhesive Layers

Adhesives are the primary source of biological risk in medical labels. Solvent-based and waterborne acrylic adhesives, hot-melt rubber adhesives, and silicone gel adhesives are tested for migratable residues such as acrylate monomers, rosin or terpene-phenolic tackifiers, plasticizers, and vulcanization accelerators, which are known causes of Type IV allergic contact dermatitis.

Inks, Coatings, and Overlaminates

UV-cured inks contain acrylate oligomers and photoinitiators that can migrate into the adhesive layer during storage. Printed samples, overprint varnishes, and laminating films are therefore included in the test matrix whenever the printed surface may face the patient or transfer substances through the construction.

Release Liners and Composite Constructions

Silicone-coated release liners are removed before use but can transfer substances into the adhesive during shelf storage. Full laminate constructions, tested as a composite, provide the most representative specimen for biological evaluation.

Finished Label Products

Whenever feasible, testing is performed on the finished label in its final processed, printed, and sterilized condition. Sterilization methods such as ethylene oxide, gamma irradiation, electron beam, and steam can alter material chemistry or generate degradation products, so post-sterilization samples are required for devices marketed in a sterile state.

Testing Items

Based on the device categorization in ISO 10993-1 and its GB/T 16886.1 counterpart, the following endpoints form the core test program for skin-contacting medical adhesive labels:

• In vitro cytotoxicity (ISO 10993-5): evaluates whether extractable substances cause cell death or growth inhibition.
• Skin sensitization (ISO 10993-10): identifies the potential to induce delayed-type hypersensitivity after repeated or prolonged exposure.
• Skin irritation and intracutaneous reactivity (ISO 10993-23): assesses the potential for local inflammatory responses at contact sites.

Depending on the contact duration, patient population, and outcome of the chemical assessment, supplementary evaluations may be added:

• Chemical characterization of extractables and leachables (ISO 10993-18) followed by toxicological risk assessment (ISO 10993-17), which is increasingly accepted as a scientific justification to reduce or waive biological tests.
• Acute systemic toxicity (ISO 10993-11) when significant migration into compromised skin or mucosa cannot be excluded.
• Ethylene oxide residue testing (ISO 10993-7) for labels sterilized with EtO.
• Extended endpoints such as repeated-dose toxicity or genotoxicity (ISO 10993-3) for long-term worn label systems, justified case by case in the biological evaluation plan.

Testing Methods

Sample Preparation and Extraction

Extraction follows ISO 10993-12. Thin label constructions of 0.5 mm thickness or less are typically extracted at a ratio of 6 square centimeters per milliliter, counting both surfaces. Polar media (physiological saline or cell culture medium) and non-polar media (such as sesame or cottonseed oil) are used in parallel to cover substances of differing solubility. Common extraction conditions include 37 degrees Celsius for 72 hours, 50 degrees Celsius for 72 hours, 70 degrees Celsius for 24 hours, and 121 degrees Celsius for 1 hour; the selected condition should simulate or moderately exaggerate clinical use without degrading the material. Positive and negative controls are included in every valid test series.

Cytotoxicity Testing

The most widely applied method is the extract elution assay using L929 mouse fibroblasts or an equivalent validated cell line. Cells are exposed to polar and non-polar extracts for approximately 24 hours, and results are graded either qualitatively on the ISO 10993-5 reactivity scale from 0 to 4 or quantitatively using colorimetric viability assays such as MTT. A cell viability of at least 70 percent relative to the blank control, or a reactivity grade not exceeding mild, is generally considered acceptable. Direct contact and agar diffusion methods serve as alternatives for specific material configurations.

Sensitization Testing

Sensitization is evaluated using the guinea pig maximization test, the Buehler occluded patch test, or the local lymph node assay. The guinea pig methods combine an induction phase with adjuvant or occlusive exposure and a subsequent challenge phase, with responses scored for erythema and edema. The local lymph node assay measures lymphocyte proliferation in mice and reports a stimulation index, where values at or above 3 indicate sensitizing potential. Test species selection, animal numbers, and humane endpoints must comply with ISO 10993-2.

Irritation and Intracutaneous Reactivity

For intracutaneous reactivity, polar and non-polar extracts are injected intradermally in rabbits, and the sites are scored for erythema and edema on a 0 to 4 scale at 24, 48, and 72 hours. A mean score difference of no more than 1.0 between the test extract and the control extract indicates the sample meets requirements. In accordance with the 3Rs principle, reconstructed human epidermis in vitro models are increasingly used as a stand-alone or screening method for cutaneous irritation, subject to regulatory acceptance.

Chemical Characterization and Toxicological Risk Assessment

Extractables and leachables studies combine simulated-use and exhaustive extractions with analytical techniques such as gas chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry, and inductively coupled plasma-mass spectrometry for elemental impurities. Identified compounds are then subjected to toxicological risk assessment under ISO 10993-17, comparing patient exposure against health-based exposure limits and threshold of toxicological concern values. This chemical pathway frequently streamlines the overall biological evaluation of label materials.

Applications

Biocompatibility evaluation of medical adhesive labels supports regulatory submissions and quality control across a broad range of healthcare products, including applications where labels contact intact or compromised skin for extended periods.

• Patient identification wristbands, including neonatal wristbands requiring heightened safety margins for sensitive skin.
• Wound dressing borders, island dressings, and securement dressings for catheters and infusion lines.
• Fixation labels and tapes for ECG electrodes, sensors, and monitoring devices.
• Transdermal delivery and topical patch systems where the adhesive interface contacts skin for 24 hours or longer.
• Labels applied to sterile device packaging and instrument trays used in operating environments.
• Specimen identification labels, blood bag labels, and cryogenic laboratory labels forming part of the medical supply chain.
• Custom-printed labels used in home healthcare and long-term wearable monitoring products.

FAQ

Which biocompatibility tests are mandatory for medical adhesive labels?

For labels categorized as surface devices contacting intact skin, ISO 10993-1 and GB/T 16886.1 call for cytotoxicity, sensitization, and irritation as baseline endpoints. The final test program must be justified in a documented biological evaluation plan that considers contact type, contact duration, and the results of chemical characterization.

Do labels that never touch the patient require biological testing?

Labels applied only to device exteriors handled by healthcare staff generally pose lower risk. In many jurisdictions, a chemical characterization study under ISO 10993-18 combined with a toxicological risk assessment under ISO 10993-17 is sufficient to justify waiving biological tests, but the rationale must be documented and accepted by the relevant regulatory authority.

Which standards apply for regulatory submission in China?

Chinese device registrations rely on the GB/T 16886 series, which is harmonized with ISO 10993. Test reports from accredited third-party laboratories, together with a biological evaluation report, are typically required as part of the product registration dossier.

Should testing be performed on raw materials or finished labels?

Finished labels in their final printed, processed, and sterilized condition are the preferred specimens, because manufacturing, printing, and sterilization can all introduce or generate new extractable substances. Raw material testing is used mainly for screening during development.

How long do the tests take?

Typical turnaround times are two to three weeks for cytotoxicity, two to three weeks for intracutaneous irritation, three to four weeks for the local lymph node assay, and six to eight weeks for guinea pig sensitization studies. Chemical characterization and risk assessment timelines depend on analytical complexity.

Can in vitro methods replace animal testing?

Reconstructed human epidermis models can replace rabbit skin irritation testing in many scenarios, and the local lymph node assay substantially reduces animal use compared with guinea pig methods. Acceptance depends on the device category and the regulatory framework, and all animal work must comply with ISO 10993-2 welfare principles.

How are results interpreted and reported?

Each study concludes with a pass or fail determination against the acceptance criteria of the specific standard, supported by control data and raw observations. The individual reports then feed into the overall biological evaluation report, which concludes whether the medical self-adhesive label is biologically safe for its intended use under the risk management system defined by ISO 14971.